ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
Phase of Trial: Phase I/II
Latest Information Update: 18 Oct 2018
At a glance
- Drugs Defactinib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ROCKIF Trial
- 10 Oct 2018 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 10 Oct 2018 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.